Expression and purification of cGMP grade NY‐ESO‐1 for clinical trials

Adam J. Lowe, Cameron Bardliving, Chung‐Jr Huang, Leonardo Maestri Teixeira, Leonardo M. Damasceno, Kyle A. Anderson, Gerd Ritter, Lloyd J. Old, Carl A. Batt

Biotechnology Progress · 2010 · 12 citations · 14 references

Concepts

Abstract

NY-ESO-1 is a cancer testis antigen expressed in numerous cancers. Initial tests have shown its efficacy as a cancer vaccine, stimulating the body's own immune response against the invading tumor. To produce enough material for phase I clinical trials, a process using current good manufacturing practices to produce clinical grade material was developed and executed. His-tagged NY-ESO-1 was expressed in C41DE3 Escherichia coli under control of the T-7 promoter. NY-ESO-1 was produced in a 20 L fed-batch fermentation utilizing a pH-stat control scheme. The protein was then purified from inclusion bodies using a three-column process that achieved a yield of over 3.4 g and endotoxin below the detection limit of 0.005 EU/μg protein.

References

14